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See related article on page 420. There is compelling evidence that the 30-day mortality rate aftercoronary artery bypass grafting (CABG) has been on the decreaseover the past 10 years. This conclusion is based, in part, on data from1991 to 2000 derived and analyzed from both a multisite nationalvoluntary database and a Veterans Administration mandatory data-base.1,2 In the voluntary database, changes in the patient risk profile
and outcomes of more than 1 million patients undergoing isolated CABG proce-
dures were analyzed. The results indicated that, over the past decade, patients
undergoing CABG were increasingly older and had more comorbidities. This was
associated with a 30% increase in the predicted relative risk for mortality, from
2.6% to 3.4%. Despite this increase in risk, however, there was a decrease in the
risk-adjusted mortality rate, from 4.8% to 2.9%. A subset analysis of the Medicare-
aged population revealed an even greater increase in the predicted mortality for this
group of patients, from 3.3% to 4.4%. The observed operative mortality rates in
patients 65 years and older, however, declined from 5.4% to 4.1%, a relative risk
reduction of 24.1%. These findings suggest that we are providing superb care to
patients with coronary artery disease amenable to surgical intervention.
Possible explanations for the decrease in the observed mortality rate despite an
increase in the expected mortality rate over the past decade include the introduction
of critical care pathways, surgical service lines, formation of cardiac surgical teams,
technical improvements in cardiopulmonary bypass, introduction of new myocardial
protection strategies and methodologies, “fast-track” management, and changes in
selection criteria.2 As a consequence, one might be inclined to believe that the
mortality rate after CABG has finally reached an acceptable level. Obviously, this
is not the case, for the only acceptable mortality after CABG is 0.0%. Moreover,
these types of studies do not take into account that the complication rates of death,
myocardial infarction (MI), severe ventricular dysfunction, and heart failure after
CABG might exceed 10% to 15% in selected patient populations, that nearly two
thirds of in-hospital deaths after CABG surgery are related to cardiovascular events,
and that the cost to the US health care system could exceed $2 billion.3 There is also
increasing evidence that the incidence of myocardial necrosis after CABG, as
measured on the basis of measurement of serum creatine kinase (CK) and its MB
isoenzyme (CK-MB), occurs more frequently than previously appreciated and is
associated with a significant decrease in medium-term and long-term survival.
In 2001, Costa and colleagues4 reported that only 38.1% of 496 patients who
underwent CABG had normal postoperative CK-MB levels. When the CK-MB
levels were stratified into cohorts of enzyme increases of normal, 1 to 3 times the
upper limits of normal (ULN), 3 to 5 or more times the ULN, and more than 5 times
the ULN, the incidence of death at 30 days after CABG was 0.0%, 0.5%, 5.4%, and
7.0%, respectively (P  .001 among the 4 groups). Late mortality rates (1 year) for
these groups were 1.1%, 0.5%, 5.4%, and 10.5%, respectively. The peak postoper-
ative cardiac enzyme level also strongly correlated with worse clinical outcome (P
 .009). Steuer and associates5 reported similar findings in 2002. These investiga-
tors examined postoperative serum aspartate aminotransferase and CK-MB levels
and their relationship to early cardiac-related death and late survival in 4911 patients
who underwent CABG consecutively during a 6-year period. They found that
elevated enzyme levels on the first postoperative day greatly increased the risk of
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early cardiac death (aspartate aminotransferase, 2.35
kat/L [odds ratio, 9.2]; CK-MB, 61 g/L [odds ratio,
6.0]) and were associated with a 40% to 50% risk increase
in late mortality at 7 years. This increased risk of death was
constant over time. Thus it is becoming increasingly clear
that biomarkers of myocardial necrosis are frequently in-
creased after CABG, and this is associated with a decrease
in short-term, medium-term, and long-term survival.
The pathophysiology of CABG-related mortality has
been under intense investigation for many years. Consider-
able evidence now exists that ischemia-reperfusion injury
plays a major role and that one of the underlying mecha-
nisms is the excess accumulation of intracellular calcium
concentrations (calcium overload). This can result in the
activation of various enzyme systems and signaling path-
ways that can lead to cell contracture, membrane rupture,
gap junction dysfunction, cell death, and cardiac enzyme
release. One process that leads to calcium overload is the
activation of the sodium-hydrogen exchanger (NHE), which
occurs during ischemia and reperfusion. NHEs are a family
of membrane proteins that are ubiquitously distributed.
Seven isoforms have been identified and are designated as
NHE-1 through NHE-7. In the heart NHE-1 is localized
primarily in the sarcolemmal membrane and is involved in
the transport of hydrogen ions in exchange for sodium ions.
During ischemia and reperfusion, activation of the ex-
changer can lead to increased intracellular sodium concen-
trations. As a consequence of increased sodium concentra-
tions, the sodium-calcium exchanger operates in the reverse
direction, and the result is calcium overload. Thus a novel
approach to attenuating or preventing myocyte injury
caused by intracellular calcium overload would be to inhibit
the activation of the NHE.
In this issue of the Journal, Boyce and colleagues6
present both a strong rationale for using such an agent
(cariporide) and compelling clinical evidence that this agent
might be beneficial in patients undergoing CABG. The
findings are quite impressive.
The primary end point of all-cause mortality or MI was
significantly reduced in the group receiving 120 mg of
cariporide (high dose) compared with the group receiving
placebo. Specifically, the event rate in the high-dose cari-
poride group was 12.2%, whereas it was 16.2% in the
placebo group (P  .027). A significant reduction in the
event rate was apparent within the first 24 hours and was
maintained throughout the 6-month follow-up period. Al-
though the mortality rates were similar across treatment
groups, a pronounced reduction in the risk of non-fatal
Q-wave and non–Q-wave MIs was observed. Treatment
with 120 mg of cariporide was associated with a 32%
relative risk reduction in nonfatal MIs when compared with
placebo. Other interesting findings include the observations
that high-dose cariporide was associated with (1) a reduc-
tion in left ventricular dysfunction–associated events com-
pared with placebo at 6 months (9.4% vs 13.5%, respec-
tively); (2) a reduction in the extent of infarction, as
indicated by peak CK-MB values; and (3) a reduction in the
event rate that was independent of whether the patients
received blood cardioplegia or crystalloid cardioplegia.
On the basis of the results of this study, one might
conclude that the myocardial necrosis that occurs during
CABG is due, in part, to inadequate myocardial protection,
that the underlying mechanism is related to activation of the
sodium-hydrogen exchanger, and that cariporide is a prom-
ising new therapy for reducing complications or death after
CABG. These are not unreasonable conclusions given that
the population studied was a large prospectively defined
cohort of the randomized, multicenter clinical trial known as
GUARDIAN.7 In the GUARDIAN trial the patients en-
rolled were at risk of myocardial necrosis caused by differ-
ent clinical settings (acute coronary syndromes, percutane-
ous transluminal coronary angioplasty, or CABG). This
study had a well-defined, clinically important, composite
end point of death or nonfatal MI. A central electrocardio-
graphic core laboratory classified all investigator-reported
ischemic events and screened serial CK-MB values and
electrocardiograms for all patients for the presence of pre-
viously unreported database-identified MI. The committee
was blinded to treatment assignments throughout the study.
All primary and secondary end points were validated by an
independent, blinded, end point validation committee. The
cardiac enzyme values were prospectively collected as part
of the study design, and the 6-month follow-up was excel-
lent, with less than 1% of the patients unavailable for
assessment. Finally, the large number of patients undergo-
ing CABG permitted a robust statistical analysis. For a
variety of reasons, however, the results of this subgroup
analysis do not conclusively demonstrate that the NHE
inhibitor cariporide is a cardioprotective agent in human
subjects.
First, these positive findings were observed in a subset of
patients, whereas in the overall GUARDIAN population, a
treatment benefit could not be demonstrated. This might
well be due to the heterogeneity of the population of pa-
tients studied, but the goal of the GUARDIAN trial was not
achieved (ie, to show a superiority of at least one of the
doses versus placebo in patients at risk of myocardial ne-
crosis).
Second, because there was no discernable dose-response
relationship in the CABG cohort, the observed benefit could
still be due to chance.
Third, the duration of drug treatment was quite variable.
Although all the patients undergoing CABG received pla-
cebo or a dose of 20 mg, 80 mg, or 120 mg of cariporide 15
minutes to 2 hours before the operation, the postoperative
treatment was variable and ranged from 1 to 7 days, with a
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median duration of 2.4 days. The investigator determined
the treatment duration on the basis of the clinical status of
the patient. This inconsistency of dosing complicates the
determination of an optimal duration of treatment. On the
other hand, pharmacokinetic modeling to establish a mini-
mum effective concentration for cariporide during surgical
intervention yielded a threshold concentration of approxi-
mately 500 ng/mL, the level reached in the majority of
patients in the 120-mg treatment arm but in few of those in
the 80-mg arm and none of those in the 20-mg arm.8
Fourth, the mortality rate was similar between the pla-
cebo group and all treatment groups. This observation,
however, should not be used to detract from the finding that
high-dose cariporide reduced the composite end point of
all-cause mortality or MI. Given the sample size per treat-
ment arm, the study did not have sufficient statistical power
to detect a treatment effect in the mortality component of
the end point alone. Another explanation for not observing
an improvement in survival with treatment after CABG in
this study might be that it could take longer than 6 months
to discern a beneficial effect on medium-term and long-term
mortality, this also raises the issue of the appropriateness of
using composite end points. Although mortality is ulti-
mately the most important end point when evaluating the
efficacy of a medical intervention, the use of this end point
alone requires the enrollment of thousands of patients be-
cause of a much smaller event rate. If the sample size is not
increased to accommodate mortality as the sole primary
event, single end point studies will be underpowered, and a
potentially effective therapeutic intervention could go un-
recognized. In this study, because a reduction in the inci-
dence of an MI or a reduction in infarct size (nonfatal end
points) have been clearly linked to increased survival, the
use of the composite end point of all-cause mortality or MI
as a primary end point is appropriate. Furthermore, because
infarction might result in immediate death without preced-
ing electrocardiographic or enzymatic evidence of myocar-
dial injury, exclusion of mortality from an end point focus-
ing on myocardial injury would underestimate the event rate
and possibly exclude the most severe events from analysis.
Although not conclusive, the results of this study are
very encouraging. The findings support the concept that
NHE inhibition is a promising novel therapeutic approach
for reducing complications and death after CABG. A defin-
itive answer will most likely have to await the results of the
EXPEDITION trial, a multicenter clinical trial that is ex-
amining the efficacy of a continuous infusion of cariporide
on short-term and medium-term outcomes after CABG.
Should this study demonstrate a salutary effect of the agent
on the composite end points of death or nonfatal MI, this
would be the first therapy to do so and would represent
significant progress toward improving the clinical outcome
of patients after CABG.
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